comparemela.com

Latest Breaking News On - மருந்துகள் கழுத்து - Page 8 : comparemela.com

Board of Jubilant Pharmova appoints Group CFO

At meeting held on 01 April 2021The Board of Jubilant Pharmova at its meeting held on 01 April 2021, has approved the appointment of Arvind Chokhany as Group Chief Financial Officer and Wholetime Director of the Company. The Board also approved Arun K Sharma as Head-Group Treasury & Chief Financial Officer of the Company. Sharma shall also be a Whole-time Key Managerial Personnel of the Company. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to re

Volumes soar at Caplin Point Laboratories Ltd counter

Caplin Point Laboratories Ltd clocked volume of 8.53 lakh shares by 14:14 IST on NSE, a 7.74 times surge over two-week average daily volume of 1.10 lakh shares V-Mart Retail Ltd, Sunteck Realty Ltd, Astrazeneca Pharma India Ltd, Happiest Minds Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 01 April 2021. Caplin Point Laboratories Ltd clocked volume of 8.53 lakh shares by 14:14 IST on NSE, a 7.74 times surge over two-week average daily volume of 1.10 lakh shares. The stock gained 11.75% to Rs.450.85. Volumes stood at 1.49 lakh shares in the last session. V-Mart Retail Ltd registered volume of 96644 shares by 14:14 IST on NSE, a 5.53 fold spurt over two-week average daily volume of 17478 shares. The stock rose 0.52% to Rs.2,800.00. Volumes stood at 24926 shares in the last session.

No Sputnik V approval yet, SEC asks Dr Reddy s for more data on vax

The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine Sputnik V , while deciding on its emergency use authorisation, a senior government official said on Thursday. In September 2020, Dr. Reddy s had partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India. The company had conducted Phase 2 trials in India with 1,500 participants. Phase three trials are underway. The Hyderabad-based pharma major had applied for its emergency licensure on February 19. The Committee looked into Dr. Reddy s application, on Thursday. Sputnik V has not received the emergency use authorisation yet, as the SEC has sought additional data, according to top sources.

Lupin Ltd in demand

Lupin Ltd is quoting at Rs 1032.15, up 1.15% on the day as on 12:49 IST on the NSE. The stock is up 57.38% in last one year as compared to a 82.28% gain in NIFTY and a 67.63% gain in the Nifty Pharma index. Lupin Ltd is up for a third straight session in a row. The stock is quoting at Rs 1032.15, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 14735.5. The Sensex is at 49611.18, up 0.21%. Lupin Ltd has dropped around 2.13% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has dropped around 0.68% in last one month and is currently quoting at 12272.6, up 0.55% on the day. The volume in the stock stood at 5.84 lakh shares today, compared to the daily average of 17.58 lakh shares in last one month.

Dr Reddys Laboratories announces acquisition of partial ownership interest in AWACS and Trikaal

Dr Reddys Laboratories announced that the company s investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has, through its wholly-owned entity DigiHealth Technologies LLP, acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private (AWACS) though a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech. It is also agreed to acquire the balance stake subject to fulfilment of certain terms and conditions. The cost of acquisition for the combined transaction of AWACS and Trikaal is approximately Rs 75 crores for acquisition of 100% stake in AWACS and Trikaal (direct and indirect together).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.